Description: Insulet’s stock price target has recently been raised, with the fair value estimate increasing from $366 to $378 following the company's Investor Day and updated outlook. This change reflects strengthened confidence in Insulet’s multi-year revenue growth potential, supported by strong sales momentum and expanding adoption in both the Type 1 and Type 2 diabetes markets. Stay tuned to discover how investors and analysts can track future shifts in Insulet’s evolving story. Analyst Price Targets...

Description: Insulet (PODD) could produce exceptional returns because of its solid growth attributes.

Description: Insulet (PODD) recently held its 2025 Investor Day, presenting a growth roadmap featuring new product launches, ambitious revenue targets, and strategies aimed at expanding both operating margins and earnings over the next several years. See our latest analysis for Insulet. Following its Investor Day, Insulet’s share price has surged, posting a 5.84% gain in a single day. This highlights investor enthusiasm for the company’s multi-year growth plans and ongoing product innovation. With a...

Description: The medtech firm plans to launch its next flagship patch-pump in 2027, and its first fully closed loop system for Type 2 diabetes in 2028.

Description: Insulet, Sandisk and O-I Glass have been highlighted in this Screen of The Week article.

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: ACTON, Mass., November 20, 2025--Insulet Corporation (NASDAQ: PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted its 2025 Investor Day at the Company’s global headquarters in Acton, Massachusetts.

Description: Insulet has outperformed the broader market over the past year, and analysts remain strongly bullish on the company’s trajectory.

Description: Upgraded broker ratings bring the spotlight to PODD, SNDK and OI as potential picks in a selective market, each showing strong earnings growth and momentum.

Description: Medtronic shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 67 to 82.

Description: DoorDash, Baidu upgraded: Wall Street's top analyst calls

Description: Boston Scientific, Insulet, BioLife Solutions and Allurion push ahead with innovation and efficiency as the Medical Products industry faces pressure.

Description: Insulet (PODD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Description: Insulet is Thursday's IBD Stock Of The Day. After a wild post-earnings reaction, Insulet stock is in a consolidation with an early entry.

Description: FLEX, PODD and PRAA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Nov. 13, 2025.

Description: Soft earnings didn't appear to concern Insulet Corporation's ( NASDAQ:PODD ) shareholders over the last week. Our...

Description: PFBC, WFRD, PODD, PRAA and ALX have been added to the Zacks Rank #1 (Strong Buy) List on Nov. 13, 2025.

Description: Insulet, Celestica and Innodata emerge as top momentum picks, each boasting strong earnings surprises and solid uptrends.

Description: The Senate's move to end the record shutdown lifts Wall Street, spotlighting momentum stocks like Insulet, Celestica and Innodata.

Description: Insulet (PODD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Description: Insulet (PODD) delivered third-quarter 2025 results that surpassed analyst predictions for both revenue and earnings. This outcome was due to meaningful expansion in its Omnipod insulin delivery system. Management boosted full-year guidance as business momentum remains strong. See our latest analysis for Insulet. Insulet’s latest breakout results have built on a year of steadily improving sentiment, powering the stock to a 24.5% year-to-date share price return and a robust 19.3% total...

Description: Insulet Corporation recently reported strong third quarter results, with revenue and earnings surpassing analyst expectations and the company raising its full-year revenue and margin guidance. Key drivers include higher demand for the Omnipod system, integration with continuous glucose monitors in Europe, and new product reimbursement approvals in Norway. We'll explore how Insulet's upward guidance, propelled by sustained Omnipod demand, could influence the company's forward-looking...

Description: Insulet (PODD) could produce exceptional returns because of its solid growth attributes.

Description: Insulet stock yo-yoed Thursday despite broadly beating sales forecasts for its body-worn insulin pump, Omnipod.

Description: While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Description: Insulet (PODD) delivered earnings and revenue surprises of +9.73% and +4.42%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 29.9% year on year to $706.3 million. On top of that, next quarter’s revenue guidance ($767.8 million at the midpoint) was surprisingly good and 5.1% above what analysts were expecting. Its non-GAAP profit of $1.24 per share was 8.1% above analysts’ consensus estimates.

Description: ACTON, Mass. AP) — Insulet Corp. PODD) on Thursday reported third-quarter earnings of $87.6 million.

Description: ACTON, Mass., November 06, 2025--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2025.

Description: Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be reporting results this Thursday before market hours. Here’s what investors should know.

Description: Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.

Description: The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Description: Align Technology jumps 15% after Q3 earnings and revenues beat estimates, though steep margin declines weigh on results.

Description: Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: Insulet Corporation (NASDAQ:PODD) is one of the best NASDAQ growth stocks to buy for the next 5 years. On October 10, RBC Capital raised the price target on Insulet to $365 from $350 and kept an Outperform rating on the shares as part of a broader research note on the MedTech sector ahead of Q3 […]

Description: ACTON, Mass., October 30, 2025--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its new campaign, "The Day Diabetes Showed Up to Work," in honor of Diabetes Awareness Month, which starts November 1.

Description: The United States Insulin Pump Market is projected to grow from US$ 1.55 billion in 2024 to US$ 2.58 billion in 2033, with a CAGR of 5.84% from 2025-2033. This growth is driven by the rising diabetes prevalence, technological innovations in insulin delivery, and increased awareness of continuous glucose monitoring and personalized diabetes care. Key players like Medtronic, Insulet, and Tandem Diabetes Care are leading the market with smart insulin pumps integrated with CGMs for automated and rem

Description: Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Description: Trying to figure out what to do with Insulet stock right now? You are definitely not alone. Over the past year, shares of Insulet have soared 36.1%, and they are up a massive 25.9% year-to-date. Even after some recent volatility, with a gain of 2.3% over the past week but a slight dip of 1.3% in the last month, many investors are wondering if there is still runway for more growth ahead or if optimism might already be priced in. A big part of Insulet’s appeal has always been its position in...

Description: Insulet will release its third-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

Description: ACTON, Mass., October 23, 2025--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Robert ("Robbie") L. Huffines, a former Global Chair of Investment Banking at JP Morgan Chase & Co., to the Company’s board of directors, effective October 31, 2025. Mr. Huffines joins the board as an independent director and will serve on the board’s Audit Committee.

Description: Intuitive Surgical's shares jump 17% after Q3 earnings and revenues beat expectations, fueled by surging da Vinci 5 placements and strong global procedure growth.

Description: Investing.com -- Stifel has resumed coverage of several medtech companies, citing steady adoption of continuous glucose monitors (CGMs) and insulin pumps as key drivers for growth.

Description: Insulet Corporation (NASDAQ:PODD) ranks among the best medical device stocks to invest in. Canaccord Genuity maintained its Buy rating on Insulet Corporation (NASDAQ:PODD) and boosted its price target from $353 to $399 on September 29. In order to incorporate the latest investor conferences and revised revenue guidance into its model, the firm marginally raised its […]